NSEI:AUROPHARMA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India.


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Aurobindo Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AUROPHARMA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.8%

AUROPHARMA

0.2%

IN Pharmaceuticals

1.2%

IN Market


1 Year Return

46.3%

AUROPHARMA

49.6%

IN Pharmaceuticals

4.3%

IN Market

Return vs Industry: AUROPHARMA underperformed the Indian Pharmaceuticals industry which returned 49.6% over the past year.

Return vs Market: AUROPHARMA exceeded the Indian Market which returned 4.3% over the past year.


Shareholder returns

AUROPHARMAIndustryMarket
7 Day-2.8%0.2%1.2%
30 Day4.9%12.4%7.1%
90 Day32.5%23.7%23.6%
1 Year47.2%46.3%51.8%49.6%6.3%4.3%
3 Year26.7%25.1%36.2%32.2%4.2%-0.7%
5 Year11.7%9.6%-0.8%-4.4%34.4%24.4%

Price Volatility Vs. Market

How volatile is Aurobindo Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aurobindo Pharma undervalued compared to its fair value and its price relative to the market?

17.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: AUROPHARMA (₹881.3) is trading above our estimate of fair value (₹499.27)

Significantly Below Fair Value: AUROPHARMA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: AUROPHARMA is good value based on its PE Ratio (17.4x) compared to the IN Pharmaceuticals industry average (22.2x).

PE vs Market: AUROPHARMA is poor value based on its PE Ratio (17.4x) compared to the Indian market (14.6x).


Price to Earnings Growth Ratio

PEG Ratio: AUROPHARMA is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: AUROPHARMA is overvalued based on its PB Ratio (3.1x) compared to the IN Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Aurobindo Pharma forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

8.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUROPHARMA's forecast earnings growth (8.7% per year) is above the savings rate (7.2%).

Earnings vs Market: AUROPHARMA's earnings (8.7% per year) are forecast to grow slower than the Indian market (24.3% per year).

High Growth Earnings: AUROPHARMA's earnings are forecast to grow, but not significantly.

Revenue vs Market: AUROPHARMA's revenue (7.7% per year) is forecast to grow slower than the Indian market (10.6% per year).

High Growth Revenue: AUROPHARMA's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AUROPHARMA's Return on Equity is forecast to be low in 3 years time (16%).


Next Steps

Past Performance

How has Aurobindo Pharma performed over the past 5 years?

8.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AUROPHARMA has high quality earnings.

Growing Profit Margin: AUROPHARMA's current net profit margins (12.6%) are higher than last year (12.3%).


Past Earnings Growth Analysis

Earnings Trend: AUROPHARMA's earnings have grown by 8.5% per year over the past 5 years.

Accelerating Growth: AUROPHARMA's earnings growth over the past year (16.9%) exceeds its 5-year average (8.5% per year).

Earnings vs Industry: AUROPHARMA earnings growth over the past year (16.9%) exceeded the Pharmaceuticals industry 15.6%.


Return on Equity

High ROE: AUROPHARMA's Return on Equity (17.7%) is considered low.


Next Steps

Financial Health

How is Aurobindo Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: AUROPHARMA's short term assets (₹164.1B) exceed its short term liabilities (₹113.9B).

Long Term Liabilities: AUROPHARMA's short term assets (₹164.1B) exceed its long term liabilities (₹7.3B).


Debt to Equity History and Analysis

Debt Level: AUROPHARMA's debt to equity ratio (33.1%) is considered satisfactory.

Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 85.5% to 33.1% over the past 5 years.

Debt Coverage: AUROPHARMA's debt is well covered by operating cash flow (78.8%).

Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (17x coverage).


Balance Sheet


Next Steps

Dividend

What is Aurobindo Pharma current dividend yield, its reliability and sustainability?

0.34%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: AUROPHARMA's dividend (0.34%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: AUROPHARMA's dividend (0.34%) is low compared to the top 25% of dividend payers in the Indian market (2.51%).


Stability and Growth of Payments

Stable Dividend: AUROPHARMA's dividend payments have been volatile in the past 10 years.

Growing Dividend: AUROPHARMA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (5.9%), AUROPHARMA's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: AUROPHARMA's dividends in 3 years are forecast to be thoroughly covered by earnings (5.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Narayanan Govindarajan (52 yo)

8.17yrs

Tenure

₹168,872,953

Compensation

Mr. Narayanan Govindarajan has been the Managing Director of Aurobindo Pharma Limited since June 1, 2012 and served as its Chief Executive Officer from October 7, 2010 to June 1, 2012. Mr. Govindarajan ser ...


CEO Compensation Analysis

Compensation vs Market: Narayanan's total compensation ($USD2.26M) is above average for companies of similar size in the Indian market ($USD1.50M).

Compensation vs Earnings: Narayanan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Narayanan Govindarajan
MD & Executive Director8.17yrs₹168.87mno data
Kambam Reddy
Vice Chairman8.17yrs₹15.12m5.68%
₹ 29.3b
Santhanam Subramanian
Chief Financial Officer6.08yrs₹21.06m0.0012%
₹ 6.3m
B. Reddy
Compliance Officer & Company Secretary4.17yrs₹4.76mno data
Meenakshi Sivakumaran
Whole-Time Director28.42yrs₹15.12m2.47%
₹ 12.8b
Mettu Madan Reddy
Whole-Time Director13.92yrs₹40.68m0.00034%
₹ 1.8m
Penaka Sarath Reddy
Whole-Time Director12.92yrs₹8.73mno data
Sanjeev Dani
COO & Head of Formulations5yrsno datano data
S. Kumar
President of Technicalno datano datano data
Krishna Kiran
Investor Relations Officerno datano datano data
G. Prasad
Senior Vice President of Global Finance & Operationsno datano datano data
Sudhir Singhi
Head of Global Finance Operationsno datano datano data

5.5yrs

Average Tenure

59yo

Average Age

Experienced Management: AUROPHARMA's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Narayanan Govindarajan
MD & Executive Director8.17yrs₹168.87mno data
Kambam Reddy
Vice Chairman8.17yrs₹15.12m5.68%
₹ 29.3b
Meenakshi Sivakumaran
Whole-Time Director28.42yrs₹15.12m2.47%
₹ 12.8b
Mettu Madan Reddy
Whole-Time Director13.92yrs₹40.68m0.00034%
₹ 1.8m
Penaka Sarath Reddy
Whole-Time Director12.92yrs₹8.73mno data
M. Sastry
Director of Aurobindo (H K ) Limitedno datano datano data
Penaka Venkata Ram Reddy
Non-Executive Director33.67yrs₹400.00k3.07%
₹ 15.9b
Mandavilli Murthy
Non-Executive Independent Director12.92yrs₹750.00kno data
Kannan Ragunathan
Independent Non-Executive Chairman8.17yrs₹1.10mno data
Savita Mahajan
Additional Non-Executive Independent Director2.67yrs₹800.00kno data
Avnit Singh
Non-Executive Independent Director5.42yrs₹650.00kno data

10.5yrs

Average Tenure

60.5yo

Average Age

Experienced Board: AUROPHARMA's board of directors are seasoned and experienced ( 10.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AUROPHARMA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Aurobindo Pharma Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aurobindo Pharma Limited
  • Ticker: AUROPHARMA
  • Exchange: NSEI
  • Founded: 1986
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹516.388b
  • Shares outstanding: 585.94m
  • Website: https://www.aurobindo.com

Number of Employees


Location

  • Aurobindo Pharma Limited
  • Water Mark Building
  • Plot No. 11
  • Hyderabad
  • 500084
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524804BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 1999
AUROPHARMANSEI (National Stock Exchange of India)YesEquity SharesININRDec 1999

Biography

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter dru ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 07:54
End of Day Share Price2020/08/13 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.